Skip to main contentLast updated: 05-Nov-2026
Dr Harsh Shah
MS, MCh (Surgical Gastroenterology), DrNB (Surgical Gastroenterology)
Registered with Gujarat Medical Council, Reg. No. G-38738
Intestine Cancer Surgeon
Dr. Jivraj Mehta Hospital, Vasna, Ahmedabad · 18 years of experience
In short
The word “small bowel cancer” covers four different tumours. They are a gland-forming cancer, a neuroendocrine tumour, a lymphoma and a GIST. Each starts in a different cell and needs a different plan.
The tissue report names the kind, and the kind decides the operation. A lymphoma is treated mainly with medicine. A GIST is removed without clearing the lymph nodes. A gland-forming cancer needs the nodes removed.
Two tests carry most weight in a gland-forming cancer. They are MMR, which can open the way to immunotherapy, and HER2, which can point to a targeted drug.
To see how these tumours are treated here, read our small bowel cancer treatment page. This post explains what the tissue report means.
The type decides the operation, the lymph node plan and whether medicine comes first. A wrong guess at the start can lead to too big an operation, or too small a one.
This is why a good tissue sample, read by a pathologist who sees these tumours often, comes before the plan.
Each kind starts in a different cell. Where it sits in the bowel, how it is staged and how it is treated all follow from that cell.
| Kind | Starts in | Where it often sits | Main treatment |
|---|---|---|---|
| Gland-forming cancer (adenocarcinoma) | The glandular lining | The duodenum, near the bile duct opening | Surgery, then chemotherapy when nodes are involved |
| Neuroendocrine tumour | Hormone-making cells | The last part of the small bowel | Surgery with clearing of the bowel’s fold, then injections or targeted treatment if needed |
| Lymphoma | Lymph cells | Often the ileum | Medicine, with surgery only for complications |
| GIST | Pacemaker cells of the gut wall | The jejunum or ileum | Surgery without node removal, and a targeted tablet when the risk is high |
How common each kind is depends on the series. Hospital series count more gland-forming cancers, because they present with a block and are operated on. For who is at risk and how rare the disease is, see our post on how rare it is.
Most are moderately formed gland cancers that look like bowel cancer under the microscope. The report lists the type, the depth, the margins and the lymph nodes.
| Line in the report | What it tells you |
|---|---|
| Type of cancer | Signet-ring and poorly cohesive types behave harder; medullary type often does better |
| Depth of growth | How far through the wall it went, which sets the stage |
| Margins | Whether cancer reaches the cut edge, which decides if more treatment is needed |
| Lymph nodes examined and involved | How reliable the stage is, and whether chemotherapy is advised |
| Vein or nerve invasion | A sign of a higher chance of return |
| MMR result | Whether immunotherapy and a family check are needed |
One line deserves attention. Survival tracks with how many nodes the pathologist found. Too few suggests the nodes were not fully cleared in the operation, so ask about it.
Three tests do. They are the MMR check on every gland-forming cancer and HER2 when the cancer has spread. A wider gene panel is added for spread disease.
These tests are about drug choice and family safety. They do not change the fact that the tumour needs to be removed when it can be.
A good share of gland-forming small bowel cancers cannot repair copying errors in their DNA. Such a tumour can respond strongly to immunotherapy, which is why this single result matters so much.
For how these results shape drug choice, read what the guidelines advise, and for the studies behind it, the key trials.
Grade says how fast the cells divide, and it is the main driver of the plan. It rests on a stain called Ki-67, a count of dividing cells, and how well formed the cells look.
| Grade | How the cells divide | What it means |
|---|---|---|
| G1 | Slowly | Usually quiet over many years |
| G2 | At a middle pace | Needs closer follow-up |
| G3, well formed | Fast, but cells look orderly | May still respond to hormone-based and radiolabelled treatment |
| Poorly formed carcinoma | Fast, and cells look disorderly | Treated like small-cell cancer, mainly with chemotherapy |
A G3 tumour with orderly cells and a poorly formed carcinoma can show the same Ki-67 number. They are different diseases. This is why the pathologist’s look at the cells matters as much as the number.
The report should show more than the grade. It should say how many tumours were found, how big and how deep. It should also say whether the nodes and the bowel’s fold are involved.
If a patient has flushing, the anaesthetist must know before any operation. Handling these tumours can set off a sudden surge of hormones, so medicine is given to prevent it.
Both are named by a small set of stains. The report then adds the details that set treatment: the lymphoma subtype, or the GIST size, cell-division count and gene change.
| Stain | Gland-forming cancer | Neuroendocrine | Lymphoma | GIST |
|---|---|---|---|---|
| Cytokeratin (gland marker) | Positive | Often positive | Negative | Negative |
| Synaptophysin, chromogranin | Negative | Positive | Negative | Negative |
| CD45, CD20, CD3 | Negative | Negative | Positive | Negative |
| KIT, DOG1 | Negative | Negative | Negative | Positive |
For how a GIST is treated, see our GIST treatment page.
Yes. Once the type is known, the operation, the margins and the lymph node plan follow. Each kind has its own rule.
| Kind | The operation | Lymph nodes |
|---|---|---|
| Gland-forming cancer | Removal of the bowel segment with its fold; near the bile duct opening, a larger operation | Cleared widely, and counted |
| Neuroendocrine tumour | Removal of the tumour and the scarred fold, even for a small tumour | Cleared with the fold |
| Lymphoma | Mainly none; surgery for a block, a tear or bleeding | Not the aim |
| GIST | Removal of the tumour with a clear edge and no rupture | Not routinely removed |
Each of these plans also depends on the stage and on your fitness. The tumour board weighs the report with the scans. For the order of tests that leads here, see our post on tests and their order.
Two things. The mix of tumours may include more neuroendocrine tumours and lymphomas than Western reports show. And gut tuberculosis can pass for a tumour at every step.
Your tissue block belongs to you. Ask for it, and bring it to the consultation.
Ask each of these without worry. A good team will answer plainly.
The answers tell you where the plan stands firm and what is still being checked.
Four different cell types can grow into a tumour in the small bowel. They are gland-forming cancer, neuroendocrine tumour, lymphoma and GIST. Each has its own tests, staging method and treatment, so the first job is to name the type from tissue.
It checks whether the tumour cells can repair their own DNA copying errors. A tumour that cannot is called MMR-deficient. This result can open the way to immunotherapy, and it can point to an inherited condition in the family.
HER2 is a protein on the surface of some cancer cells. When a tumour carries too much of it, drugs that target HER2 may help in spread disease. The test is usually sent when the cancer has spread.
The grade tells you how fast the cells are dividing. It comes from a stain called Ki-67 and a count of dividing cells. The pathologist also says whether the cells look well formed or poorly formed, and this matters as much as the grade.
Yes, in most cases. A small set of stains separates the four kinds. Lymphoma lights up for blood-cell markers, and GIST lights up for KIT and DOG1. A pathologist who sees many such tumours gives the most reliable answer.
Gut tuberculosis can look like a tumour on scans and on a small biopsy. Sending fresh tissue for TB tests avoids calling a treatable infection a cancer, or the other way round.
If the report is unclear or the type is in doubt, a second review is reasonable. Choose a pathologist who sees these tumours often. Your surgeon can arrange it and bring the slides to the tumour board.
For the full range of small bowel tumour care, start at the small bowel cancer treatment page. For questions before you travel, call +91-63555-64601.
Dr Harsh Shah — Dr. Jivraj Mehta Hospital, Vasna, Ahmedabad
Dr. Jivraj Mehta Hospital, Dr Jivraj Mehta Marg, Vasna, Ahmedabad 380007.
Consultations, review of reports and scans, operations and follow-up. OPD Monday to Saturday, 9 am to 5 pm.
Appointments: +91-63555-64601 · +91-63590-11009 · Hospital 079-2663 6363
Directions to the hospital · WhatsApp +91-63555-64601
Did your tissue report use words you could not follow, such as grade, MMR or KIT, and did nobody explain them? Bring the report to Dr Harsh Shah. He will tell you which kind of small bowel tumour it names and what each line changes in your plan. Call, or send a message on WhatsApp. Call +91-63555-64601 Ask on WhatsApp
Swasth Parivar: every week, practical advice on recovery, diet and warning signs. No advertising. Stop any time.
Your number is used for these updates and for the clinic to reach you. It is never sold or passed on. To stop, reply STOP on WhatsApp.